- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05974657
Effectiveness and Safety of Lactobacillus Acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea
Lactobacillus Acidophilus LA85 for Preventing Antibiotic-Associated Diarrhea: A Multi-Centric, Double-Blind, Randomized Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized, placebo-controlled, double-blind clinical trial aims to assess the effectiveness and safety of probiotics as food supplements in preventing antibiotic-associated diarrhea. The study will enroll 82 patients who will be randomly assigned to either the experimental group or the placebo group. Participants in the experimental group will receive a probiotic supplement containing Lactobacillus acidophilus LA85, while those in the placebo group will receive a non-active substitute.
The outcomes include the following measurements:
- Number of days until the onset of diarrhea.
- Duration of diarrhea, if it occurs.
- Evaluation of gastrointestinal quality of life using the GIQLI questionnaire.
- Overall patient satisfaction with the intervention. Throughout the trial, a double-blind approach will be maintained, ensuring that both the participants and the investigators are unaware of the treatment assignments. This helps minimize bias and ensures the reliability of the results. To assess the efficacy and safety of probiotics, data will be collected and analyzed using appropriate statistical methods. The number of days until the onset of diarrhea will be compared between the two groups, as well as the duration of diarrhea if it occurs. Gastrointestinal quality of life will be evaluated using the GIQLI questionnaire, which measures various aspects related to gastrointestinal well-being. Additionally, overall patient satisfaction with the intervention will be assessed. By conducting this comprehensive clinical trial, we aim to provide valuable insights into the potential benefits and safety of probiotics as food supplements in preventing antibiotic-associated diarrhea. The results obtained will contribute to evidence-based recommendations for healthcare professionals and may have implications for improving patient outcomes and quality of life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Castelldefels
-
Barcelona, Castelldefels, Spain, 08860
- Ciurana Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients starting antibiotic treatment (Amoxicillin 750mg).
- Patients prone to diarrhea with the administration of Amoxicillin 750mg.
- Patients over 18 years of age.
- Patients of both sexes.
- Patients capable of understanding the clinical study and who are committed to complying with the requirements and procedures of the study.
- Patients who have signed the informed consent.
Exclusion Criteria:
- Diabetic patients.
- Pregnant patients.
- Patients who are breastfeeding.
- Patients who require pharmacological treatment that triggers drug diarrhea (laxatives, antacids with magnesium, chemotherapy, omeprazole, esomeprazole, lansoprazole, rabeprazole, cimetidine ranitidine, mycophenolate nizatidine, ibuprofen, naproxen and metformin).
- Patients requiring treatment with tricyclic antidepressants, antiepileptics, antihistamines, antiparkinsons, antipsychotics, antispasmodics, verapamil, monoamine oxidase inhibitors, opiates, sympathomimetics, antacids (with aluminum and calcium), non-steroidal antidiarrheals and anti-inflammatory drugs.
- Patients who change the type of diet during the study.
- Patients with an allergy or intolerance to any of the ingredients in the formulation of the product under study.
- Subjects with a history of drug, alcohol or other substance abuse, or other factors that limit their ability to cooperate during the study.
- Subjects whose condition does not make them eligible for the study, according to the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
Composition: 400mg maltodextrin (excipient); Capsule total weight: 400mg; Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose); Secondary conditioning:Cardboard case Secondary packaging content:14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals; Storage:Store in a cool, dry place without exposure to the sun.
|
Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
|
Active Comparator: Probiotic group
Composition: 20mg (2x109 UFC/ capsule) Lactobacillus acidophilus LA85 (active principle) and 380mg maltodextrin (excipient); Capsule total weight: 400mg; Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose); Secondary conditioning:Cardboard case Secondary packaging content:14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals; Storage:Store in a cool, dry place without exposure to the sun.
|
Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diarrhea Onset Time
Time Frame: 14 days
|
Evaluate stool characteristics on the Bristol Scale (Degree 5-7 indicative of diarrhea).
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joan Ciurana, Dr., Dentist Ciurana Clinic
- Principal Investigator: Xavier Calvo, Dr., Dentist Rob Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WK2023001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated
Clinical Trials on Probiotic Lactobacillus acidophilus LA85
-
Vancouver Island Health AuthorityCanadian Society of Hospital Pharmacists; Jamieson Laboratories Ltd, CanadaTerminatedDiarrhea | Clostridium DifficileCanada
-
DaniscoCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnDiarrhea | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Pablo Román LópezCompleted
-
University of North Carolina, Chapel HillDaniscoCompletedAbdominal Pain | Bloating | Functional Bowel Disorders | Abdominal Discomfort
-
Huaqiu ZhangNot yet recruitingIschemia | Cognitive Impairment | Cerebrovascular Ischemia
-
Huaqiu ZhangNot yet recruitingCognitive Impairment | Ischemia; Cerebrovascular
-
Bio-K Plus International Inc.JSS Medical Research Inc.CompletedDiarrhea | Clostridium InfectionsCanada